Cadila Healthcare, a Rs.4,450 crore Ahmedabad based pharma giant, has suffered a setback due to significant higher interest burden and other manufacturing cost. The consolidated net profit for the second quarter ended September 2011 declined by 39.9 per cent to Rs.102.68 crore from Rs.170.84 crore in the corresponding period of last year. Its consolidated net sales increased by 10.2 per cent to Rs.1,220 crore from Rs.1,106 crore. EBDITA remained almost flat at Rs.248.11 crore during the quarter under review. With fall in profits, its earnings per share declined to Rs.5.01 from Rs.6.34 in the last period. Its interest burden went up to Rs.76.86 crore from Rs.16.04 crore and employees cost grew by 29.7 per cent to Rs.180.29 crore from Rs.133.01 crore.


For the first half ended September 2011, Cadila's consolidated net sales increased by 10.7 per cent to Rs.2,393 crore from Rs.2,161 crore in the similar period of last year. Its EBDITA improved marginally by 1.4 per cent to Rs.556.81 core from Rs.548.92 crore. However, its net profit declined by 10.1 per cent to Rs.332.50 crore from Rs.370.02 crore.